These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 33204588)
1. Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia. Kar S; Mottamal M; Al-Horani RA ChemistryOpen; 2020 Nov; 9(11):1161-1172. PubMed ID: 33204588 [TBL] [Abstract][Full Text] [Related]
2. Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies. Al-Horani RA; Parsaeian E; Mohammad M; Mottamal M Chem Biol Drug Des; 2022 Jul; 100(1):64-79. PubMed ID: 35377529 [TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors. Argade MD; Mehta AY; Sarkar A; Desai UR J Med Chem; 2014 Apr; 57(8):3559-69. PubMed ID: 24666186 [TBL] [Abstract][Full Text] [Related]
4. Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa. Kar S; Bankston P; Afosah DK; Al-Horani RA Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577586 [TBL] [Abstract][Full Text] [Related]
5. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. Al-Horani RA; Ponnusamy P; Mehta AY; Gailani D; Desai UR J Med Chem; 2013 Feb; 56(3):867-78. PubMed ID: 23316863 [TBL] [Abstract][Full Text] [Related]
6. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Yang L; Sun MF; Gailani D; Rezaie AR Biochemistry; 2009 Feb; 48(7):1517-24. PubMed ID: 19178150 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor. Obaidullah AJ; Al-Horani RA Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):40-48. PubMed ID: 28552062 [TBL] [Abstract][Full Text] [Related]
15. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Wong PC; Jiang X Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in the discovery and development of factor XI/XIa inhibitors. Al-Horani RA; Afosah DK Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants. Hussain Z; Cooke AJ; Neelamkavil S; Brown L; Carswell E; Geissler WM; Guo Z; Hawes B; Kelly TM; Kiyoi Y; Lai K; Lesburg C; Pow E; Zang Y; Wood HB; Edmondson SD; Liu W Bioorg Med Chem Lett; 2020 Aug; 30(16):127072. PubMed ID: 32340773 [TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of aptamers targeting factor XIa. Woodruff RS; Ivanov I; Verhamme IM; Sun MF; Gailani D; Sullenger BA Thromb Res; 2017 Aug; 156():134-141. PubMed ID: 28644959 [TBL] [Abstract][Full Text] [Related]
19. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. Schaefer M; Buchmueller A; Dittmer F; Straßburger J; Wilmen A J Mol Biol; 2019 Dec; 431(24):4817-4833. PubMed ID: 31655039 [TBL] [Abstract][Full Text] [Related]
20. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation. Sinha D; Marcinkiewicz M; Navaneetham D; Walsh PN Biochemistry; 2007 Aug; 46(34):9830-9. PubMed ID: 17676929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]